Chlordiazepoxide HCl/Clidinium Bromide capsules, 5 /2.5 mg, 100-count bottle, Rx Only, Manufactur...
FDA Drug Recall #D-1035-2016 — Class III — April 18, 2015
Recall Summary
| Recall Number | D-1035-2016 |
| Classification | Class III — Low risk |
| Date Initiated | April 18, 2015 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Valeant Pharmaceuticals North America LLC |
| Location | Bridgewater, NJ |
| Product Type | Drugs |
| Quantity | 564,454 bottles |
Product Description
Chlordiazepoxide HCl/Clidinium Bromide capsules, 5 /2.5 mg, 100-count bottle, Rx Only, Manufactured in Canada by: Valeant Pharmaceuticals International, Inc., Steinbach, MB R5G 1Z7 Canada; Manufactured for: Oceanside Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807, NDC 68682-409-10.
Reason for Recall
Failed Impurities/Degradation Specifications
Distribution Pattern
Nationwide and Puerto Rico
Lot / Code Information
Lot #: 13G005P, 13G010P, Exp 06/16; 3H029P, 13J048P, 13J049P, 13J050P, Exp 08/17; 14B047P, 14B048P, 14B049P,14C043P, 14C048P, 14C049P, Exp 01/18; 14D048P, 14D053P, 14D054P, Exp 03/18; 14G042P, 14G047P, 14G049P, Exp 5/18; 14J005P, 14J006P, 14J007P, Exp 07/18; 14K114P, 14K115P, 14K116P, Exp 09/18; 15B008P, 158013P, 15B021P, 15C058P, 15C059P, 15C064P, Exp 01/19; 15E037P, 15E038P, Exp 04/19
Other Recalls from Valeant Pharmaceuticals North America...
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0487-2019 | Class III | Cardizem CD (diltiazem HCl) capsules, 120 mg, p... | Jan 30, 2019 |
| D-0490-2019 | Class III | Cardizem CD (diltiazem HCl) capsules, 300 mg, p... | Jan 30, 2019 |
| D-0488-2019 | Class III | Cardizem CD (diltiazem HCl) capsules, 180 mg, p... | Jan 30, 2019 |
| D-0491-2019 | Class III | Diltiazem HCl CD capsules, 360 mg, 90-count bot... | Jan 30, 2019 |
| D-0489-2019 | Class III | Cardizem CD (diltiazem HCl) capsules, 240 mg, p... | Jan 30, 2019 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.